ANGPTL3 and liver dysplastic nodule: Therefore, we hypothesized that combining anti-ANGPTL3 and IL-22 could simultaneously reduce proteinuria, mitigate the inflammatory response, and regulate metabolism homeostasis to achieve better DN treatment outcomes.